Carcinoids and large cell neuroendocrine carcinomas (LCNECs) are rare neuroendocrine lung tumors. Here we provide an overview of the most updated data on the molecular characteristics of these diseases. Recent genomic studies showed that carcinoids generally contain a low mutational burden and few recurrently mutated genes.
Introduction
Neuroendocrine lung tumors represent approximately 20% of all lung cancers and can be subdivided into typical carcinoids (TCs) (1.8%), atypical carcinoids (ACs) (0.2%), large cell neuroendocrine carcinomas (LCNEC) (3%), and SCLCs (5%). [1] [2] [3] These tumors have in common an organoid architecture (with rosettes and peripheral palisading), but TCs and ACs are of low-and intermediate-grade malignancy, respectively, whereas LCNECs and SCLCs are high-grade tumors. Histologically, TCs and ACs are distinguished by the presence of mitosis *Corresponding author.
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(<2/mm 2 for TC and 2-10/mm 2 for AC) and necrosis; LCNEC and SCLC are separated on the basis of cytological criteria (cell size and nuclear features). 4 Although the incidence of SCLC seems to have decreased, in past years an increase in the incidence of carcinoids and LCNEC had been reported. [1] [2] [3] 5 TCs occur in adults around 45 years of age on average (and may even occur in children and adolescents), which is earlier than ACs (55 years) and LCNEC/SCLC (65 years). 1, 6 The vast majority of patients with TCs are nonsmokers, whereas ACs seem to be slightly more frequent in smokers. Conversely, LCNEC and SCLC are almost exclusively related to cigarette smoking, with more than 90% of the patients being heavy smokers. Patients with a TC have a more favorable prognosis than patients with an AC, 1 and patients with both carcinoid subtypes have a better prognosis than patients with LCNEC or SCLC. 7 For most carcinoids surgical management is possible, whereas patients with LCNEC and SCLC generally have metastatic disease at diagnosis, limiting the surgical options. 1, 6 Nevertheless, when carcinoids have metastasized (10%-23% of TCs and 40%-50% of ACs), they are difficult to treat on account of high resistance to radiotherapy and chemotherapy. 1 Therefore, neuroendocrine lung tumors, in general, are in need of additional effective (systemic) therapies. To identify novel and promising therapeutic options, large sequencing efforts have been performed on these tumors over the past years, with a major focus on SCLC. [8] [9] [10] Only recently, these genomic studies have also been carried out in the rare neuroendocrine lung tumors carcinoids and LCNEC. Here, we comprehensively review recent genomic studies on pulmonary carcinoids and LCNEC and briefly address alterations identified in SCLC.
Genomic Studies on Rare Lung Neuroendocrine Lung Tumors

Carcinoids
Two studies extensively profiled carcinoids: Fernandez-Cuesta et al. investigated 69 carcinoids by RNA sequencing (RNAseq) and 44 tumor-normal pairs by whole-genome sequencing or whole-exome sequencing (WES) ( Table 1) . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Simbolo et al. used a discovery-screen approach that included profiling tumor-normal tissue samples from 14 carcinoids by WES and 23 tissue samples by targeted sequencing on 418 genes. 24 Armengol et al. and Vollbrecht et al. also analyzed a few cases using standard next-generation sequencing cancer panels (see Table 1 ). 14, 15 Copy number variations have been assessed by Affymetrix 6.0 SNP arrays 11 (n ¼ 54) and by a next-generation sequencing panel 12 (n ¼ 88) (Table 2 11 -13,17-19,24 ). In total, 150 TCs and 65 ACs have been assessed by whole-genome sequencing, WES, or targeted sequencing.
Carcinoids are characterized by a low mutation rate (0.4 mutations/Mb), and contrary to SCLC, they are not enriched for G:C>A:T transversions, which are characteristic of smoking exposure. 11 Statistically significant mutated genes reported by Fernandez-Cuesta et al. 11 included menin 1 gene (MEN1) (9%), eukaryotic translation initiation factor 1A, X-linked (EIF1AX) (9%), and AT-rich interaction domain 1 (ARID1A) (7%). The most frequently mutated genes identified by Simbolo et al. 12 were MEN1 (11%), tumor protein p53 gene (TP53) (10%), lysine methyltransferase 2C gene (KMT2C) (also called MLL3) (8%), ARID1A (6%), DS cell adhesion molecule like 1 (DSCAML1) (5%), lysine methyltransferase 2D (KMT2D) (also called MLL2) (5%), notch 2 gene (NOTCH2) (5%), and piccolo presynaptic cytomatrix protein gene (PCLO) (5%). Overall, the most frequently somatically mutated gene in carcinoids is MEN1 (11%-22%), which is usually accompanied by loss of heterozygosity. 11, 12, 25 In addition, germline mutations in this gene are found in 2% of patients with pulmonary carcinoid, 26 usually associated with the multiple endocrine neoplasia 1 syndrome.
27
MEN1 is a histone modifier that acts as a scaffold protein assembling the MEN1-MLL-PC4 and SFRS1 interacting protein 1 gene (PSIP1) ternary complex. Interestingly, another member of this complex, PSIP1, has also been found to be recurrently mutated (5%) in carcinoids in a mutually exclusive way with MEN1. 11 The MEN1 complex promotes the expression of cyclin-dependent kinase inhibitor 2A gene (CDKN1B) (P18
Ink4c
) and cyclindependent kinase inhibitor 2C gene (CDKN2C) (P27 Kip1 ), both of which are cell cycle inhibitor genes. Although MEN1 is more highly expressed in carcinoids than in normal tissue, gene mutations are associated with reduced gene expression, and both mechanisms are associated with poor prognosis in pulmonary carcinoids. 25 Similar to MEN1, most of the other genes mutated in pulmonary carcinoids are involved in chromatin remodeling, a process that controls gene expression in cells by opening/closing chromatin structure allowing/ preventing transcriptional regulatory proteins to bind DNA. Genes related to chromatin remodeling can be divided into covalent histone-modifying complexes (acetylation, methylation, phosphorylation, and ubiquitination) and adenosine triphosphate-dependent chromatin remodeling complexes (such as the SWI/ SNF). Globally, both Fernandez-Cuesta et al. 11 and Simbolo et al. 12 reported mutations in chromatin remodeling genes with a high frequency (40% and 46%, respectively): mutations have been detected in SET domain bifurcated 1 gene (SETDB1), lysine demethylase 4A, PHD finger protein 8 gene (PHF8), jumonji domain containing 1C gene (JMJD1C), nuclear receptor binding SET domain protein 1 gene (NSD1), bromodomain and WD repeat domaining containing 3 gene (BRWD3), and histone deacetylase 5 gene (HDAC5) and in genes of the Polycomb complex 11, 12 ; the KMT2 (MLL) family of covalent histone modifiers was found to be mutated in 14% of the cases 12 ; genes of the SWI/SNF complex were mutated in 22% of carcinoids, mostly affecting genes of the ARID1 family but also affecting B-cell CLL/lymphoma 11A gene (BCL11A), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 gene (SMARCA1), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 gene (SMARCA2), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 gene (SMARCA4), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 gene (SMARCB1), and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 (SMARCC2). 11, 12 Finally, other mutated genes included sister-chromatid cohesion genes, involved in DNA replication (such as dicer 1 Tumor suppressor genes such as TP53, RB1, and ATM serine/threonine kinase gene (ATM) were found mutated in 6% to 10% and deleted in 13% to 23% of the cases. 1, 12 Whereas only a few mutations in KRAS have been identified in carcinoids, [11] [12] [13] [14] mutations in the PI3K/ AKT/mTOR pathway were detected in 2% of the cases 12 and gain of function was described for phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha and RPTOR independent companion of MTOR complex 2 in 11% and 29%, respectively. By Sanger sequencing, recurrent kinase domain mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) (exon 9 and 20) have been described in 13% of TCs and 39% of ACs. 28 These results highlight an important role of the PI3K/AKT/mTOR pathway in a subgroup of carcinoids. 12 In addition, few microRNA studies have been carried out in recent years, [29] [30] [31] [32] [33] [34] but no recurrent microRNA related to progression of disease has been validated in carcinoids. 35 Finally, molecular alterations associated with highly aggressive tumors have been observed in few carcinoids: a hypermutated profile was detected in two carcinoids carrying DNA polymerase theta gene (POLQ) mutations, which are known to make cells prone to DNA doublestrand breaks and homologous recombination. 12 Also, one carcinoid showed a chromothripsis phenotype that affected genes related to chromatin remodeling. 11 An overview of the molecular characteristics of pulmonary carcinoids is provided in Figure 1 , Table 3 , and Supplementary Data 1.
All these data are extracted from studies mostly involving TCs or mostly focusing on targeted sequencing in ACs; hence, a full characterization of ACs would be needed to better appreciate the differences with TCs. However, the available preliminary data suggest that ACs might carry more alterations in PIK3CA and MEN1 genes than TCs: PIK3CA mutations and copy number gains were respectively detected in 13% and 3.8% of the TCs analyzed versus in 39% and 23% in ACs. 28 Similarly, MEN1 was found mutated with a frequency of 20% to 22% in ACs and 6% in TCs. 25 Moreover, MYCL protooncogene, bHLH transcription factor gene (MYCL), SRC proto-oncogene, non-receptor tyrosine kinase gene (SRC), and BCL2, apoptosis regulator (BCL2) amplifications were exclusively seen in ACs. 12 These differences may explain the difference of aggressiveness between these two carcinoid subtypes but this requires further investigation.
LCNECs
Only one study, led by George et al., 23 has performed multiomics analyses on a relatively large number of samples, by WES on 60 matched tumor-normal cases, RNAseq on 69 tumors, and Affymetrix 6.0 SNP arrays for copy number variations on 60 tumors (Tables 1 and 2) . Additionally, seven studies evaluated LCNEC using FFPE and custom targeted sequencing panels (Simbolo et al. 12 [n ¼ 27], Rekhtman et al. 17 Tables 1 and 2 ). Only George et al., 23 Simbolo et al., 12 and Rekhtman et al. 17 included matched normal tissue in their analyses.
Similar to SCLC, LCNEC presents with a high mutation rate (8.5-10.5 mutations/Mb) 11, 17 and a mutation signature strongly associated with smoking (C:G>A:T). 23 In general, most of the reported mutated genes in LCNEC are tumor suppressor genes, with the mutations being usually accompanied by loss of heterozygosity. George et al. 23 reported statistically significant mutations in TP53 (92%), RB1 (42%), STK11 (30%), and KEAP1 (22%), and in genes of the RAS-pathway (KRAS/NRAS/ Harvey rat sarcoma viral oncogene homolog [HRAS] [10%]). The same genes were found altered in the other reported studies, although with some variation in the frequencies (see Table 3 and Supplementary Data 1). RB1 mutations seem to happen in a mutually exclusive way with mutations in STK11 (p < 0.0001 17, 21, 23 ), KEAP1 (p < 0.001 23 ) , and the KRAS/NRAS/HRAS pathway genes (including amplifications [p <0.05 17 ]). Therefore, at least two subtypes of LCNEC have been suggested: one with RB1 alterations, which is also the hallmark of SCLC disease, 9 and a second one with alterations in STK11/ KEAP1/RAF-pathway genes, a mutational pattern more , and others genes such as NK2 homeobox 1 (NKX2-1) (also known as TTF1) (10%), fibroblast growth factor receptor 1 (FGFR1) (7%), and insulin receptor substrate 2 (IRS2) (3%). In addition, Rekhtman et al. identified amplifications in v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog gene (MYCN) (2%), SRY-box 2 gene (SOX2) (11%), and cyclin E1 gene (CCNE1) (9%). 17 The other studies have also identified amplifications in RPTOR independent companion of MTOR complex 2 gene (RICTOR) (11%) and KRAS (3%). Cyclin-dependent kinase inhibitor 2A (CDKN2A) (P16 ink4a ) deletions were reported with a frequency of in 4% to 8%; mutual exclusiveness of CDKN2A deletions with RB1 mutations has been recently described. 37 Other molecular alterations identified in LCNEC include mutations in genes of the NOTCH Simbolo et al. 12 suggested that carcinoids and highgrade neuroendocrine carcinomas (SCLC and LCNEC) have similar mutation frequencies in these remodeling pathways (46% versus 55% respectively [P ¼ 0.32]); Rekhtman et al. detected these genes mutated in LCNEC at an even higher frequency (78%). They have even described a carcinoid-like subtype of LCNEC having lower Ki-67 expression along with MEN1 mutations, but the existence of such a subtype requires further evaluation.
17
PI3K-AKT-mTOR mutations have been identified in 15% to 49% of the LCNEC cases analyzed. 12, 17 However, except for recurrent phosphatase and tensin homolog gene (PTEN) (7% in George et al. 23 ) and PI3KCA mutations (11% in Simbolo et al. 12 ), mutations in other genes of this pathway have yet to be confirmed in other studies. Several mutations unique to LCNEC were reported by George et al., 23 including the metalloproteinases ADAM metallopeptidase with thrombospondin type 1 motif 12 gene (ADAMTS12) (20%) and ADAM metallopeptidase with thrombospondin type 1 motif 2 gene (ADAMTS2) (15%), as well as growth arrest specific 7 gene (GAS7) (12%) and neurotrimin gene (NTM) (10%), both of which are related to neuroendocrine differentiation and neurogenesis. Simbolo et al. 12 also reported mutations in SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 gene (SMARCA2) (11%) and Rekhtman et al. 17 reported mutations in neurotrophic receptor tyrosine kinase 2 gene (NTRK2) and neurotrophic receptor tyrosine kinase 2 gene (NTRK3) (19%), genes that have been previously reported mutated in LCNEC. 38 Finally, Miyoshi et al. 18 found that laminin subunit alpha 1 gene (LAMA1), PCLO, and multiple EGF like domains 8 (MEGF8) were statistically significantly more frequently mutated in LCNEC than in SCLC (p ¼ 0.019, 0.023, and 0.015, respectively). Preliminary expression analyses on a limited number of LCNEC samples (n ¼ 8 39 and n ¼ 28 40 ) suggest that LCNEC can be subdivided into different subtypes, only partly clustering with SCLC. In the studies of George et al., which include RNAseq expression data for 69 LCNECs 23 and 110 SCLCs, 9 the authors have found that despite their mutational patterns, LCNECs with STK11/ KEAP1 mutations exhibit a neuroendocrine profile with closest similarity to SCLC tumors (referred to as type 1 LCNEC), whereas those LCNECs harboring RB1 mutations have reduced levels of neuroendocrine markers and high activity of the NOTCH pathway (referred to as type II LCNEC). Contradictory conclusions were drawn by the study of Karlsson et al. on the basis of expression microarray data on 14 LCNECs. The authors made some observations that led them to speculate about a possible link between the mutational groups and their transcriptional landscape; however, they acknowledged the limited number of LCNEC cases in the two mutational groups (11 versus three) and the need for larger studies to validate these results. 20 An overview of the molecular characteristics of LCNEC is provided in Figure 1 , Table 3 , and Supplementary File 1.
A general overview of the recurrent genetic alterations identified in carcinoids and LCNEC, along with from SCLC recently reviewed by Swanton and Govindan, 36 is presented in Table 3 . In summary, recent studies have identified important genetic overlap between LCNEC and SCLC tumors with frequent mutations in the TP53 and RB1 genes. Similarly, both lung cancer types have a high mutational burden and a mutational signature related to smoking exposure. Nevertheless, LCNEC has a unique transcription profile different from that of SCLC. Furthermore, LCNEC tumors frequently harbor mutations commonly identified in NSCLC, such as those in the KEAP1, STK11, and KRAS genes. This pattern is different from that in carcinoids, which present with a low mutation rate and a lack of a smoking mutational signatures and in which the most frequently mutated genes are those involved in chromatin remodeling.
Cells of Origin
Pulmonary neuroendocrine tumors are believed to develop from normal neuroendocrine cells (Kulchitsky cells) present in the bronchi and bronchiole, where they can form neuroendocrine bodies. 41, 42 The location of neuroendocrine tumors in the lung is not random (i.e., a proximal-to-distal distribution is observed moving from the trachea to the alveolar compartment). SCLC and TCs are generally central (in the bronchi), ACs are found to Figure 1 . Overview of the most relevant molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinoma (LCNEC). Slides stained by hematoxylin-eosin saffron showing proliferation and differentiation. Original magnification, Â200 for all types. In the atypical carcinoid slide, two mitoses (arrow) are counted. In the LCNEC slide, the mitotic index is higher than 10 mitoses per 2 mm 2 (arrowheads), necrosis is frequent (star), and a rosette formation is observed (arrow). Abbreviations: TP53, tumor protein p53 gene; RB1, retinoblastoma 1 gene; ATM, ATM serine/threonine kinase gene; E1F1AX, eukaryotic translation initiation factor 1A, X-linked gene; NOTCH2, notch 2 gene; PCLO, piccolo presynaptic cytomatrix protein gene; FGFR1, fibroblast growth factor receptor 1 gene; NKX2-1, NK2 homeobox 1 gene; SOX2, SRY-box 2 gene; NTM, neurotrimin gene; GAS7, growth arrest specific 7 gene; ADAMTS2, ADAM metallopeptidase with thrombospondin type 1 motif 2 gene; ADAMTS12, ADAM metallopeptidase with thrombospondin type 1 motif 12 gene; STK11, serine/threonine kinase 11 gene; KEAP1, kelch like ECH associated protein 1 gene; CDKN2A, cyclin-dependent kinase inhibitor 2A gene; PI3K, phosphoinositide 3-kinase gene; mTOR, mechanistic target of rapamycin gene. 
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Chromatin remodeling SWI/SNF complex Histone (methyl/ acetyl) transf E3 ubiquitin-protein ligase be central and peripheral, and LCNEC is generally peripheral. 43 Diverse cell(s) of origin may explain these differences in the anatomic location.
Pulmonary neuroendocrine cell hyperplasia (PNECH) can arise in the context of carcinoids or adenocarcinoma development, but also as a reaction to inflammation. 44, 45 Hence, only diffuse idiopathic neuroendocrine cell hyperplasia, a generalized proliferation of pulmonary neuroendocrine cells that includes tumorlet formation, is recognized as a preinvasive condition of carcinoids development in the WHO classification of lung tumors. 42, 45 Interestingly, the ortopedia homeobox gene (OTP), which has been recently identified as a specific marker for pulmonary carcinoids, is highly expressed in pulmonary neuroendocrine cell hyperplasia but not in neuroendocrine cells and neuroendocrine bodies. 46, 47 Genetically engineered mouse models for neuroendocrine carcinomas include, among others, knockouts for RB1/TP53, RB1/TP53/PTEN, or RB1/TP53/p130 in basal, neuroendocrine, Clara, and alveolar epithelial type 2 cells. 48 When neuroendocrine cells were targeted, SCLC was the major cancer that developed in these mice, except in the RB1/TP53/PTEN knockout, in which LCNEC tumors also developed. Interestingly, in the RB/TP53/ p130 knockout that targeted all lung cells, LCNEC was much more frequent, suggesting that LCNEC can develop not only from neuroendocrine cells but also from nonneuroendocrine cells. This was further supported by a mouse model in which LCNEC tumors generally grew peripherally around the bronchial-alveolar duct junction and specifically expressed a Clara cell marker (secretoglobin family 1A member 1). 49 Previous studies have hypothesized that LCNEC is clonally related to both NSCLC (including lung adenocarcinomas and squamous cell lung cancer) and SCLC. 17, 23 In two studies on combined NSCLC-LCNEC tumor samples (n ¼ 16), the proportion of shared mutations between the two histologically different components ranged from 4% to 99%. 18, 50 These results point to a common progenitor cell for the different components, as it has been recently described for other nonpulmonary combined neuroendocrine carcinomas. 51, 52 If the different components of a combined LCNEC have a common origin, the next question would be what the primary component is. Thus far, only transdifferentiation (or dedifferentiation) of a nonneuroendocrine NSCLC toward high-grade neuroendocrine carcinoma (SCLC or LCNEC) has been described. This transdifferentiation can occur in lung adenocarcinomas with activating EGFR mutations (exon 19 deletion or exon 21 L858R) as a resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment (3%-14%). [53] [54] [55] [56] The main mechanism for the transdifferentiation has been ascribed to biallelic inactivation of RB1 (previously suggested to also modulate neuroendocrine gene expression 57 ), which would be absent in the NSCLC component and enriched in the SCLC/LCNEC component. 18, 55, 56, 58 Moreover, in a recent study with genome data on 21 patients with EGFR-mutant NSCLCs that were transdifferentiated into SCLCs upon TKI treatment, the authors found that EGFR TKI-resistant SCLCs branched out early from the NSCLC clones that harbored completely inactivated RB1 and TP53. 59 Finally, loss of NOTCH has also been suggested as an alternative pathway of nonneuroendocrine cells to develop SCLC 16 and LCNEC 23 on the basis of evidence on mice models and human-derived tumor gene expression analysis showing that elevated NOTCH can reverse the neuroendocrine phenotype. 9, 23 An illustration of the possible cells of origin in pulmonary neuroendocrine tumors is provided in Figure 2 .
Prognostic Value of Molecular Alterations
In terms of prognosis, some studies have evaluated the molecular characteristics of patients with carcinoid with a good versus bad prognosis (n ¼ 10 in the discovery cohort and n ¼ 54 in the validation cohort). 24, 46 In carcinoids with poor prognosis, the proto-oncogene RET was up-regulated along with genes involved in cell cycle control, such as abnormal spindle microtubule assembly gene (ASPM), baculoviral IAP repeat containing 5 gene (BIRC5), BUB1 mitotic checkpoint serine/threonine kinas gene (BUB1), kinetochore scaffold 1, centrosomal protein 55 gene (CEP55), Fanconi anemia complementation group A gene (FANCA), histone cluster 1 H3 family member B gene (HIST1H3B), origin recognition complex subunit 6 gene (ORC6L), regulator of chromosome condensation 1 gene (RCC1), and ubiquitin conjugating enzyme E2 C gene (UBE2C). 46, 60 Important downregulated genes included folate receptor 1 gene (FOLR1), folate receptor 3 gene (FOLR3), discs large MAGUP scaffold protein 2 gene (DLG2), beta-1,3-glucuronyltransferase 1 gene (B3GAT1), kirre 3 like nephron family adhesion molecule 3 gene (KIRREL3), and FXYD domain containing ion transport regulator 2 gene (FXYD2), all of which are localized in chromosome 11q (loss of which has been previously found to have prognostic value). 24 The prognostic value of the OTP gene and the stem cell marker CD44 has been validated in larger series (n ¼ 288), confirming that their loss of expression is associated with poor prognosis. 46, 47, 61 MEN1 mutations and chromosomal alterations are also related to poor prognosis in carcinoids, 12, 24, 25, 62 suggesting that mechanisms causing chromosomal alterations and tumor instability might be related to histopathological grade progression, although this needs further evaluation.
In the case of LCNEC, a higher frequency of copy number gains in members of the MYC family (MYC, MYCL1, and MYCN) has been detected in advanced-stage (n ¼ 13) versus in early-stage (n ¼ 65) LCNEC (p ¼ 0.002). 18 In addition, a recent study has also shown in an SCLC mouse model that overexpression of the transcription factor nuclear factor I B gene (NFIB) promotes metastatic spread. This was further supported by the finding that this gene is frequently overexpressed in human metastatic high-grade neuroendocrine lung tumors. 63 An illustration of the genes related to progression of disease in pulmonary neuroendocrine tumors is provided in Figure 2 .
New Treatment Possibilities Based on Genomic Data
Carcinoids
In terms of therapeutic targets, few targetable mutations have been identified in carcinoids apart from the PI3K/AKT/mTOR pathway. PI3K pathway inhibitors have recently shown clinical effectivity in advanced and progressive lung carcinoids, with a prolonged progressionfree survival of 11.0 months (range 9.2-13.3) compared with 3.9 months (range 3.6-7.4) upon supportive care. 64 Nevertheless, studies comparing biomarkers from this pathway to predict response to mTOR inhibitors have yet to be provided. Several additional inhibitors are currently being investigated in carcinoids, including cabozantinib (mesenchymal-epithelial transition, vascular endothelial growth factor receptor 2), regorafenib (vascular endothelial growth factor receptor 2-tyrosine kinase with immunoglobulin-like and EGFRlike domains 2 [a multireceptor TKI]), nintedanib (vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet derived growth factor receptor), sufatinib (vascular endothelial growth factor receptor, fibroblast growth factor receptor 1), carfilzomib (20S proteasome inhibitor), and ibrutinib (Bruton's TKI); they were recently extensively reviewed elsewhere. 65 Thus far, two case reports have reported echinoderm microtubule-associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene (ALK) rearrangements in patients with ACs, but only one of them responded to crizotinib (ALK receptor tyrosine kinase [first-generation]) treatment. 66, 67 The data generated in the available genomic studies suggest that a successful treatment of carcinoids with small molecule inhibitors is rather unlikely; however, further studies on larger series are warranted.
LCNEC
Because of the heterogeneous response, standard treatment for LCNEC is debated, as some clinicians favor SCLC-type chemotherapy (platinum-etoposide) whereas others prefer NSCLC-type chemotherapy regimens (gemcitabine/taxane/pemetrexed combined with platinum). [68] [69] [70] [71] [72] The fact that LCNEC tumors share mutations with SCLC (TP53/RB1) and NSCLC (STK11/KEAP1/RASpathway genes) may explain the observed heterogeneous response to chemotherapy. 17 Recent analysis of 79 LCNEC cases found that those tumors harboring a wild-type RB1 had a better outcome when treated with NSCLC-type chemotherapy (platinum-gemcitabine or paclitaxel) than with SCLC-type therapy, whereas no differences in outcome were observed for LCNECs carrying an inactivated RB1 gene. 21 Interestingly, in a prospective SCLC study, RB1 wild-type status was correlated with resistance to SCLC-type (platinum-etoposide) chemotherapy. 73 These studies suggest that molecular profiling, specifically for RB1, in LCNEC and SCLC may guide choice of chemotherapy treatment.
Two-thirds of the LCNEC tumors seem to harbor molecular alterations potentially targetable (n ¼ 45 [Rekhtman et al. 17 ]), and these potential therapeutic targets are more often present in RB1 wild-type (84%) than in RB1-mutated (50%) tumors. Targetable alterations include EGFR mutations (±2%), BRAF mutations (±1%), and FGFR1 amplifications (±3%). In a recent study, a V600E (G469R) BRAF-mutated LCNEC showed response to a BRAF inhibitor. 74 Three case reports have described clinical activity for gefitinib or icotinib (EGFR [first generation]) in LCNEC with activating EGFR exon 19 deletions. 75, 76 However, treatment with crizotinib of LCNEC with EML4-ALK rearrangement was ineffective. 77 Hence, standard routine screening for activating (targetable) mutations should be encouraged in the context of LCNEC tumors.
Genes related to the PI3K-AKT-mTOR pathway are occasionally mutated in LCNEC (Table 3) . The results from a phase II clinical trial combining carboplatinpaclitaxel chemotherapy with daily everolimus maintenance treatment (mTOR [first generation]) showed encouraging results. 78 However, the survival results were only slightly better than those reported for an European chemotherapy phase II trial 67 and a retrospective study with taxane chemotherapy. 72 Evaluation of RB1 status and mTOR pathway genes might be interesting to select patients with LCNEC with improved treatment response.
A humanized monoclonal antibody directed against delta like Notch canonical ligand 3 gene (DLL3), a ligand of NOTCH, conjugated to a DNA-damaging pyrrolobenzodiazepine dimer toxin has recently been tested as an antitumorigenic drug for LCNEC and SCLC. DLL3 expression was detected by immunohistochemistry in 65% of LCNECs and 72% of treatment-naive SCLCs. In a recent phase IA/IB second-/third-line dose escalation and expansion study for DLL3-antibody therapy in SCLC and LCNEC, evidence for clinical activity was provided, particularly, for high-DLL3-expressing tumors. antibody against PD-L1 was assessed, none of them were positive (0% [H-score >1]), but only very few metastatic carcinoid cases have been analyzed. 81, 82 Recently, it was reported that the mutational burden might be related to response to immunotherapy. 83, 84 Considering the very low mutational burden in (typical) carcinoids, PD-L1 therapy might not be effective in these tumors. Figure 2 . Proposed overview of the cells of origin and prognostic molecular alterations in carcinoids and large cell neuroendocrine carcinoma (LCNEC). Abbreviations: alt, alternative; morph, morphology; TKI, tyrosine kinase inhibitor; del, deletion; amp, amplification; mt, mutation; STK11, serine/threonine kinase 11 gene; KEAP1, kelch like ECH associated protein 1 gene; MEN1, menin 1 gene; RET, ret proto-oncogene gene; TP53, tumor protein p53 gene; RB1, retinoblastoma 1 gene; ASCL1, achaete-scute family bHLH transcription factor 1 gene; NSCLC-NED, NSCLC with neuroendocrine differentiation; rep, replication; OTP, orthopedia homeobox gene; NFIB, nuclear factor I B gene.
However, the response of patients with carcinoids showing chromothripsis or a hypermutation profile requires further evaluation. In LCNEC, checkpoint blockade therapy showed encouraging results on a retrospective multicenter cohort involving 10 patients (five of them receiving third-line treatment, all in good performance [0-1]), with six partial responses and a long progression-free survival for the overall cohort (median 57 weeks [range ). 85 PD-L1 in a study on early-stage LCNEC was expressed in up to 34% of tumors (n ¼ 72), 86 but this frequency is much lower in other cohorts (10.4% and 0% in two series of 106 and 11, respectively). 81, 82 The mutational burden is very high in LCNEC (>8 mutations/Mb) and is related to PD-L1 expression. Some LCNECs may therefore show favorable response to immunotherapy, 17, 23, 86 and consequently, a PD-1 inhibitor (pembroluzimab) is currently being investigated in this tumor type (phase II [NCT02939651]).
Conclusions
New insights into the molecular background of neuroendocrine tumors still support the separation of TCs and ACs from LCNEC and SCLC. 43 Carcinoids are recognized by frequent mutations in chromatin remodeling genes, although molecular alterations are in general rare. The currently available genomic data suggest that the potential application of targeted therapies in patients with carcinoids might be limited, apart from targeting the PI3K-AKT-mTOR pathway, which requires further testing. Future studies should focus on the multiomics analyses of larger series of samples, with a special focus on ACs, which remain largely understudied. Taking into account the confirmed role of chromatin remodeling processes in the development of these tumors, major emphasis should also be put on studying the methylation patterns of pulmonary carcinoids.
In the case of LCNEC, molecular data show that LCNEC should be considered as a unique group of neuroendocrine tumors separate and different from SCLC. Stratification of LCNEC tumors on the basis of their molecular characteristics may be clinically relevant for the choice of chemotherapy regimen. Possible targetable mutations in LCNEC include mutations in EGFR and BRAF in a small subpopulation, necessitating routine screening in clinical practice. The efficacy of targeted treatment can nevertheless be debated in cases harboring an inactivated RB1. Delta like Notch canonical ligand 3 antibody therapy may be relevant for LCNEC and requires further investigation. Finally, immunotherapy might be an option for the treatment of LCNEC and also possibly for carcinoids with a hypermutation profile, although clinical response to checkpoint blockade therapy in these rare tumors is currently lacking.
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